INTRODUCTION {#s1}
============

Somatic gene fusions are a common feature of many human cancers and have been found prevalent in leukemia, sarcoma, as well as epithelial cancers such as thyroid, prostate, colorectal, and breast cancer \[[@R1], [@R2]\]. CSGF data have been well-curated and publically available through the Mitelman Database of Chromosome Aberrations and Gene Fusions in cancer \[[@R2]\], the COSMIC database \[[@R3]\], the TICdb \[[@R4]\], as well as in publications \[[@R5]--[@R7]\]. Genome-wide studies of CSGFs, especially in hematological malignant diseases, have considered the involvement of chromatin structure \[[@R8]\] and timing during replication \[[@R9]\] as putative genomic susceptibilities for the arising of CSGFs. Recently, CSGFs have been systematically identified in tumor samples of The Cancer Genome Atlas (TCGA) project \[[@R6]\] and in cancer cell lines \[[@R5]\]. These highly heterogeneous data have been offering an unprecedented opportunity to study the arising mechanisms and function of CSGFs.

Cancers evolve by a reiterative somatic process of clonal expansion, genetic diversification and clonal selection within the adaptive landscapes of tissue ecosystems. \[[@R10], [@R11]\], relying on the somatic dynamics of genomic features and functions. Individual oncogenic fusions can also have inherent tumor suppression property \[[@R12]\]. Meanwhile, the natural history of genes links to diseases, especially for cancers \[[@R13], [@R14]\]. It appears that arsing mechanisms and genomic functions of CSGFs are highly heterogeneous \[[@R15]--[@R21]\]. Meanwhile, little known is whether there are distinct phylogenomic and genomic features of CSGFs involved genes. In this study, we sought to link the phylogenomic and genomic features of CSGFs involved genes to potential arsing mechanisms and function categories of CSGFs by leveraging the rich resources of omics data.

RESULTS {#s2}
=======

CSGF data sets and annotation settings {#s2_1}
--------------------------------------

We collected six curated datasets of CSGFs (Table [1](#T1){ref-type="table"}), including the COSMIC \[[@R22]\], the cancer cell line fusion data (Genetech) \[[@R5]\], TICdb \[[@R4]\], the ensemble cancer landscape fusion data \[[@R7]\], Mitelman fusion data (Mitelman) \[[@R23]\], and the TCGA fusion data (TCGA) \[[@R6]\]. Toward a comprehensive annotation of CSGFs involved genes, we also collected a number of functional genomic data sets (Table [1](#T1){ref-type="table"}), including the reference human genomic ENSEMBL data \[[@R24]\], protein-protein interactions \[[@R25]\], the FANTOM expression data \[[@R26], [@R27]\], GTEX data \[[@R28]\], the standard gene expression data set \[[@R29]\], Illumina\'s body map \[[@R30]\], the draft human proteome \[[@R31], [@R32]\], the gene and gene family age curation \[[@R14]\], the human gene expression atlas \[[@R33]\], as well as the TCGA data \[[@R34]--[@R36]\]. Of note, these data sets have been well recognized for their quality. Many are standard setting yet highly heterogeneous, raising substantial challenge for signals capturing in terms of the following analysis. Thus, if significant signal captured, it may have much implications.

###### List of CSGF data and annotation settings

  Data description                                      Abbreviation   PMID
  ----------------------------------------------------- -------------- ----------
  the COSMIC database                                   COC            25355519
  the TCGA fusion data                                  CLF            25485619
  the database of translocation breakpoints in cancer   TIC            17257420
  the curated cancer landscape gene fusions             BKF            23539594
  The Mitelman gene fusion database                     MIF            17361217
  the gene fusion in cancer cell lines                  TCF            25500544
  Su AI expression data 2004                            SAIe           15075390
  the curated protein coding                            CPCh           24939910
  the draft human proteome                              DHPe           24870542
  protein-protein interaction network                   PPIn           25416956
  The Cancer Genome Atlas                               TCGA           25109877
  Ensembl                                               ENSe           25352552
  Fantom5                                               FANt           24670764
  tissue-expression map                                 TEMe           25613900
  Illumina Body map                                     IBMe           24217909
  GTEX expression                                       GTEx           25954003
  gene age curated                                      GACu           20492640
  human gene expression atlas                           HGEa           20379172
  somatic mutation rate and replication time            SMRr           23770567

These data include six gene fusion sets and thirteen annotation data settings.

Genome wide preference pattern of genes as 5′ partner (5′FG) or 3′ partner (3′FG) of CSGFs {#s2_2}
------------------------------------------------------------------------------------------

Little is known about the genome wide preference pattern of being 5′FG or 3′FG of CSGFs. Of the 12,849 unique CSGFs collected from the resources listed in Table [1](#T1){ref-type="table"}, we found 5,980 genes at 5′ (or N terminal at the protein coding level) and 7,150 genes at 3′ (or C-terminal at the protein coding level), as well as 3,357 genes observed at both directions. The top 20 most frequent CSGFs involved genes have distinct preferences of being involved in 5′FG or 3′FG (Figure [1A](#F1){ref-type="fig"}). For examples, *ALK* is frequently fused at the 3′ end while *RARA* is more frequently fused at the 5′ end (Figure [1A](#F1){ref-type="fig"}). The genome-wide distribution is shown in the Bland-Altman plot, illustrating the global asymmetry (*n* = 12,848, Kolmogorov-Smirnov test D = 0.54, *p*-value \< 2.2e-16) (Figure [1B](#F1){ref-type="fig"}). Thus, it appears that being as 5′FG or 3′FG is highly asymmetric at both the global and individual gene levels, indicating a potential link of gene features to the arising of CSGFs.

![Genome wide preference pattern of genes as 5′ partner (5'FG) or 3′ partner (3'FG) of CSGFs\
(**A)** The distributions of the top 20 frequent CSGFs involved genes in terms of preference of 5'FG or 3'FG in the fusion gene sets. (**B)** The distribution of CSGFs involved genes is illustrated with the Bland-Altman plot (*n* = 12848, Kolmogorov-Smirnov test D = 0.54, *p*-value \< 2.2e-16). The x-axis (average) indicates the average frequency of each involved gene in terms of 5′ and 3′, while the y-axis (difference) indicates the difference between 5′ and 3′ frequency of each gene.](oncotarget-08-66769-g001){#F1}

*Euteleostomes* genes and *Bilateria* gene families are more likely to be involved in CSGFs {#s2_3}
-------------------------------------------------------------------------------------------

To exploit phylogenomic profile of CSGFs involved genes, we collected three phylogenomic profile data sets, including the gene age database Protein historian \[[@R37]\], as well as two additional curated data sets \[[@R14], [@R38]\]. As shown Table [2](#T2){ref-type="table"}, the origins of most recurrent fusions involved genes are almost of a vertebrate origin. CSGF involved genes are significantly enriched of the *Bilateria* origin in terms of gene family (Figure [2A](#F2){ref-type="fig"}) and *Euteleostomes* origin (Figure [2B](#F2){ref-type="fig"}) of gene age. The 3′ portion of driver CSGFs set (COC3, from the COSMIC data set) is among the highest enriched set of genes. Consistently, CSGFs involved genes are more related to whole genome duplication events (Figure [3](#F3){ref-type="fig"}), but not small scale genome duplication events (Figure [4](#F4){ref-type="fig"}). These phylogenomic data appear to support a view that cancer is more likely a vertebrate-specific disease \[[@R39]\].

###### Origins of most recurrent fusions involved genes

  vertebrate specific domain combination   vertebrate specific duplication   metazoan specific domain
  ---------------------------------------- --------------------------------- --------------------------
  SLC34A2                                  BCL6                              RARA
  MLL                                      CHD7                              ERG
  RET                                      MLL                               
  FGFR1                                    IGH2                              
  ABL1                                     ETV6                              
  MYC                                      NUP98                             
  EML4                                     RUNX1                             
  BCR                                      PAX5                              
  PML                                      EWSR1                             
  TMPRSS2                                  TRB2                              
  MAGI3                                    IGL2                              
  PVT1                                     HMGA2                             
  MLL                                      PDGFRB                            
  FGFR1                                    ALK                               
  ROS1                                     ETV1                              
  ABL1                                     RSPO2                             
  MYC                                      ALK                               
  NDRG1                                    AKT3                              
  AF4                                      RSPO3                             
  TACC1                                                                      

![Phylogenomic profiles of cancer fusion involved genes\
The gene family ages (upper) and the gene ages (lower) of the CSGF involved genes. The x-axis shows the distinct phylogenetic ages with corresponded the birth of distinct species. The y-axis indicates the proportion of each stratified phylogenetic ages. The abbreviation of each category is described to Table [1](#T1){ref-type="table"} while the '5' or '3' postfix indicates the 5′ or 3′ involved genes respectively. The "Genome" category represents the average level of genes of the human genome.](oncotarget-08-66769-g002){#F2}

![CSGFs involved genes are more related to whole genome duplications (WGD)\
**(A)** The proportion of gene origin involved in the WGD event. **(B)** The proportion of gene origin not involved in the WGD event. **(C)** Fold enrichment of gene origin involved in the WGD event. **(D)** Fold enrichment involved in whole genome duplication. The abbreviation of each category is described to Table [1](#T1){ref-type="table"} while the '5' or '3' postfix indicates the 5′ or 3′ involved genes respectively.](oncotarget-08-66769-g003){#F3}

![CSGFs involved genes are under-presented with small scale genome duplications\
(**A, B**) The proportion of genes origin involved the small scale genome duplication event and non-involved. (**C, D**) Fold enrichment involved in small scale duplication. The abbreviation of each category is described to Table [1](#T1){ref-type="table"} while the '5' or '3' postfix indicates the 5′ or 3′ involved genes respectively.](oncotarget-08-66769-g004){#F4}

The asymmetric sequence pattern of CSGFs involved genes {#s2_4}
-------------------------------------------------------

Notably, there are at least four mechanisms by which how translocations arise: synthesis mediated end joining, breakage-fusion-bridge cycles, RAG-mediated translocation and AID-mediated translocation \[[@R40]\]. To gain insights into the arising mechanisms of CSGFs, we carried out global analysis of genomic sequence features of CSGFs involved genes, including the GC content defined as (G+C)/(T+G+C+A), the GC skew defined as the ratio of (G−C)/(G+C), and the AT skew defined as the ratio of (A−T)/(A+T)), as well as the S defined as the summary of GC skew and AT skew. An emerging asymmetric pattern of these basic sequence measurements can be utilized for prediction of R-loop formation \[[@R41]\]. R loops are three-stranded nucleic acid structures comprised of nascent RNA hybridized with DNA template while leaving the non-template DNA single-stranded \[[@R42]\]. R loops are considered more unstable intermediates of RNA-DNA structure and are preferentially formed when the non-template strand is G rich \[[@R43]\].

It appears to be AT rich in the 5′ partners of the CSGF driver set (COC, the COSMIC CSGF drivers) and GC rich in the 3′ partners (Figure [5A](#F5){ref-type="fig"}, scaled heatmap plot). Due to the highly heterogeneous nature of our collected data, the GC and AT skew features of CSGFs involved genes are highly heterogeneous (Figure [5B--5D](#F5){ref-type="fig"}). However, distinct strand asymmetric patterns of fusion genes were still observed (kernel density plot, Figure [5E](#F5){ref-type="fig"}) by using three parameters for measuring the strand asymmetries, including GC skew, AT skew and S composition. There is a significant GC skew towards the 5′ fusion partners (Figure [5E](#F5){ref-type="fig"}, *P* \< 2.2e-16). Moreover, the AT-skew distribution shows that all fusion-involved genes are more AT asymmetric when compared to the background coding sequences (*P* \< 2.2e- 16, Figure [5E](#F5){ref-type="fig"}). Consistently, the S composition shows a significant asymmetric distribution of CSGFs involved genes (*P* \< 2.2e-16, Figure [5E](#F5){ref-type="fig"}).

![GC and AT skew features of CSGFs involved genes\
(**A, B, C,** and **D**) The GC and AT skew features of CSGF involved genes. GC skew, (G−C)/(G+C); AT skew, (T−A)/(A+T). Distinct strand asymmetric patterns of fusion genes are illustrated by Kernel density plotting of the three parameters for strand asymmetries including GC skew, AT skew and S composition. (**E**) The distribution patterns of GC-skew show the significant GC skew specific to the 5′ partner specific CSGFs involved genes (*P* \< 2.2E-16). (**F**) The AT-skew variable distributions shows all fusion involved genes are more AT asymmetric compared to the background coding sequences (*P* \< 2.2E-16). (**G**) A plot of the distribution of S composition measurement (S = GC_skew +AT_skew), show significant asymmetric distribution of CSFiGs (*P* \< 2.2E-16). genome: the human genome, common: coding sequences involved as both 5′ partner and 3′ partner in the CSGF data sets, F3Gu: coding sequences involved as the 3′ partner, F5Gu: coding sequences involved as the 5′ partner. The vertical intersected lines indicate the median value of the variables of each category.](oncotarget-08-66769-g005){#F5}

Since the DNA breakpoint sequence of CSGFs can reveal distinct translocation mechanisms, we set out to examine the motif patterns of known CSGFs breakpoints. The breakpoint sequences were downloaded from TICdb (Release 3.3, August 2013). Of note, we first analysis the global pattern of these breakpoints ([Supplementary Figure S1](#SD1){ref-type="supplementary-material"}), indicating an asymmetric pattern of the tetra-nucleotide distribution. Further, we performed detained key CSGFs analysis. As shown in Figure [6A](#F6){ref-type="fig"}, there is a direct correspondence between R-loop signature (GGG) with IgH class switch recombination signature (WGCW) (Spearman correlation coefficient *ρ* = 0.51, *p* = 1.57e-90). However, it is only a subset of CSGFs characterized by R-loops and an IgH switch signature (Figure [6B](#F6){ref-type="fig"}). Related CSGFs were listed, including Ig-MYC (Figure [6C](#F6){ref-type="fig"}). Thus, given these signals, our sequence analysis results support the potential of R-loops involved in arising mechanism in a subset of CSGFs.

![G-clusters, which initiate R loop formation, and on the number of WGCW sites, at a subset of CSGF breakpoint sequences\
The breakpoint sequences were downloaded from the TICdb (release 3.3: August 2013). (**A**) R-loop signature (GGG) is significantly correlated with IgH switch class recombination signature (WGCW) (Spearman correlation coefficient *ρ* = 0.5068, *p* = 1.57e-90). (**B**) The distribution of GGG and WGCW sites. (**C**) CSGFs are characterized by IgH class switch recombination signatures.](oncotarget-08-66769-g006){#F6}

Distinct genomic features including gene expression breath of CSGFs involved in genes {#s2_5}
-------------------------------------------------------------------------------------

The polarity is also found in other genomic events, such as alternative splicing, disordered region, and the human-mouse non-synonymous evolution rate (dN) (Figure [7D](#F7){ref-type="fig"}). Gene expression breadth is a measurement of the number of tissues in which a given gene is expressed. Based on the Unigene reference dataset comprised of 45 body sites, we found that fusion genes' 5′ partners have greater gene expression breadth than their 3′ partners, independent of tissue selectivity or specificity (Figure [8A--8C](#F8){ref-type="fig"}). Therefore, fusion genes' 3′ partners are more tissue --specific.

![Illustrating distinct features of CSGF involved genes based on genome features\
(**A**) F3Gs and F5Gs appear to be highly GC rich. GC, (G+C)/(A+T+C+G) for the coding strand. (**B**) Longer gene length (from the transcription start site to the poly adenalyation signal site. (**C**) More transcripts, indicative of more alternative splicing forms. (**D**) Higher non-synonymous mutation rate (dN) for the comparison between human and mouse othologs.(**E**) Lower mutation rate represented with human-mouse synonymous changes (dS). (**F**) Distinct replication origin signatures of 5′ or 3′ cancer somatic involved gene are illustrated, (**G**) Gene activity markers H3K4Me3 enrichments of different gene sets, including cancer genes (COSMIC v72 cancer genes), F3Gu (CSGFs involved 3′specific genes), F5Gu (CSGFs 5′ involved specific genes), FGcommon (genes involved in 3′ and 5′ both), and Metastasis (metastasis gene set).](oncotarget-08-66769-g007){#F7}

![Asymmetric patterns of gene expression pattern and GC content of UTRs of cancer somatic gene fusion involved genes\
The expression of CSGFs involved genes show the polarity of CSGFs at the expression level. The y-axis shows tissue numbers in terms of gene expression with distinct threshold of reference RNA-seq data, including 5 (**A**), 10 (**B**), or 20 (**C**) FPKM (fragments per kilobase per million). (**D**) 5′UTR comparison, Wilcoxon rank sum test, W = 257,110, *P* = 1.95e-05. (**E**) 3′ UTR comparison, Wilcoxon rank sum test with continuity correction, W = 129,190, *P* = 0.53. (**F**) Promoter comparison, Wilcoxon rank sum test, W = 18896, *P* = 0.94.](oncotarget-08-66769-g008){#F8}

We further examined the asymmetric pattern at the promoter, 5′ UTR and 3′ UTR of transcripts, as well as encoded protein levels of the CSFGs. Core promoter regions, the 1.5 kb region spanning upstream 1 kb and downstream 0.5 kb from the transcription start site (TSS) of CSGFs (COSMIC driver fusions), show asymmetry in CpG count ([Supplementary Figure S2A](#SD1){ref-type="supplementary-material"}), TpA count ([Supplementary Figure S2B](#SD1){ref-type="supplementary-material"}), G4 (GGGG) counts ([Supplementary Figure S2C](#SD1){ref-type="supplementary-material"}), and C4 (CCCC) counts ([Supplementary Figure S2D](#SD1){ref-type="supplementary-material"}). The significant sequence features between CSGFs involved 5′ genes and 3′ genes (Two-sample Kolmogorov-Smirnov test *p*-value \< 2.2e-16) indicate that 5′ sequence features might be related to the formation of CSGFs. Indeed, 5′ partners in CSGFs show lower overall GC content (Figure [8D](#F8){ref-type="fig"}, Wilcoxon rank sum test, W = 257,110, *p*-value = 1.95e- 05) but 3′UTR partners in CSGFs doesn\'t show significant difference in GC content (Figure [8E](#F8){ref-type="fig"}, Wilcoxon rank sum test with continuity correction, W = 129,190, *p*-value = 0.53) and promoters (Figure [8F](#F8){ref-type="fig"}, W = 18,896, *p*-value = 0.94). Intriguingly, protein stability related motif of the N-terminal sequences of FG5 and FG3 reveal an asymmetric patterns the second to the 10 amino acid of CSGFs (COSMIC driver fusions) 5′ partners (A) (Figure [9](#F9){ref-type="fig"}). Since the N-terminal amino acids are crucial protein degradation \[[@R44]\], indicating protein stability might be another critical level of cancer gene fusion functions in turn cancer somatic evolution.

![Asymmetric patterns the second to the 10 amino acid of CSGFs (COSMIC driver fusions) 5′ partners (A) and 3′ partners (B)\
Two matrices based on the frequency of first ten amino acids of the encoded peptides encoded by the 5 and 3 involved genes of CSGFs are plotted with logo diagram respectively. The two diagrams depict distinct patterns of the 5 partners (A) and 3partners.](oncotarget-08-66769-g009){#F9}

The connection of somatic copy number alterations and CSGFs {#s2_6}
-----------------------------------------------------------

Somatic copy number alterations (SCNAs) play critical roles in activating oncogenes and inactivating tumour suppressors via affecting a larger fraction of the genome in cancers than any other type of somatic genetic alterations \[[@R45]--[@R47]\]. However, little is known about the connection between SCNAs and CSGFs. Here we intersect the SCNAs and CSGFs at individual primary tumour sample level of the 13 type of cancers in TCGA. Intriguingly, among the nine potential combinations, the amplification-amplification (A−A) type is significantly enriched (Figure [10](#F10){ref-type="fig"}, around 3.8-fold over-representation, *P* = 0, binomial test. Details are presented in [Supplementary Table S1](#SD1){ref-type="supplementary-material"}). However, the amplification-deletion (A−D) and deletion-amplification (D−A) types are significantly under-represented with 0.11 (BH adjusted *P* = 7.2e-222) and 0.12 (BH adjusted *P* = 8e-217) fold of the expectations, respectively (Figure [10](#F10){ref-type="fig"}). The result is detailed in [Supplementary Table S1](#SD1){ref-type="supplementary-material"}. The finding suggests that CSGFs are dynamically evolved in amplification. Hence, we conclude that a large number of CSGFs with amplification are selected during somatic evolution of tumours.

![The relationship between CSGFs and SCNAs\
Both the CSGFs and SCNAs were derived from the TCGA data. To extract a set of high confidence CNVs, a threshold of 0.2 in segment mean value for amplifications and −0.2 for deletions were employed. The observed and expected nine types of combinations (A stands for amplification; N, normal; D, deletion) were plotted. Chi-squared (*X*^2^) test, *X*^2^ = 4375, df = 8, *P* \< 2.2e--16. The amplification-amplification (A−A) type is significantly enriched (around 3.8 fold ovepresentation, *P* = 0, binomial test). Meanwhile, both the amplification-deletion (A−D) and deletion-amplification (D−A) types are significantly underrepresented with BH adjusted *P* = 7.22e--222 and *P* = 7.98e-217, respectively.](oncotarget-08-66769-g010){#F10}

Functional exploration of CSGFs and CSGFs involved genes {#s2_7}
--------------------------------------------------------

We further examined the asymmetric patterns of functional combinations in CSGFs. We interrogated the TCGA 13-cancer data sets with known kinase (KI) genes \[[@R48]\] and transcription factors (TF) \[[@R49]\]. As shown in the [Supplementary Table S2](#SD1){ref-type="supplementary-material"}, there are a substantial number of combinations, yet the TF-KI combination is more enriched that is KI-TF (with 3.3- and 2.1-fold enrichment, respectively, and adjusted BH *p* values 5.5e-22 and 3.3e-7, successively). Since most kinases are related to protoncogene function while TFs are enriched in tumor suppressors, it is most likely that 5′ partners have higher propensity to be tumour suppressor while 3′ partners have a larger likelihood to be proto-oncogene. Intriguingly, we further examined the asymmetric pattern of FG5 and FG3 at other levels, including intrinsic protein disorder and cancer signalling pathways. As shown in [Supplementary Figure S3](#SD1){ref-type="supplementary-material"}, the F5Gs (cancer somatic gene fusions involved 5′ genes) have a higher gene expression breadth and higher intrinsic disorder region score while the F5Gs have more transcripts and longer gene length. Meanwhile F5Gs and F3Gs (cancer somatic gene fusions involved 3′ genes) were asymmetrically mapped to the key cancer gene pathways ([Supplementary Figure S4](#SD1){ref-type="supplementary-material"}). Thus, it appears to be a functional stratification of CSGFs in terms of F5Gs and F3Gs.

Given that most cancer deaths are due to the development of metastases \[[@R50], [@R51]\], we examined whether CSGFs involved genes are enriched metastasis genes. Based on PubMed search and collected gene settings, we curated a tumour metastasis gene set \[[@R52], [@R53]\]. As shown in [Supplementary Figure S7](#SD1){ref-type="supplementary-material"}, there is a 3.7-fold enrichment of the metastasis genes in the fusion genes setting collected in the COSMIC database (*P* \< 5.4e-20, hypergeometric test). The 63 CSGFs involved genes are also listed in the [Supplementary Table S3](#SD2){ref-type="supplementary-material"}. It appears that CSGFs may have critical role during tumour metastasis.

Network properties of CSGF involved genes {#s2_8}
-----------------------------------------

Next we explored the network properties of CSGF involved genes in the human protein interaction networks. The centrality distribution of cancer related genes, including SMG (somatically mutated cancer driver genes), CPG (cancer predisposition genes), GCG (GWAS cancer associated genes), GMG (HGMD cancer genes), and WGG (human genome genes), are shown in [Supplementary Figure S5](#SD1){ref-type="supplementary-material"}. CSGF involved genes have a similar distribution pattern compared to putative cancer genes ([Supplementary Figure S5](#SD1){ref-type="supplementary-material"}). Meanwhile, there is an asymmetric pattern of the centrality of 5′ and 3′ partners ([Supplementary Figure S6](#SD1){ref-type="supplementary-material"}) and the 5′ partners have less degree that their 3′ counterparts ([Supplementary Figure S6](#SD1){ref-type="supplementary-material"}, Kolmogorov-Smirnov test, *n* = 5155, D\^= 0.5, *p*-value \< 2.2e-16). It is likely that those physical interacted pairs are susceptible to become gene fusion pairs. Thus, CSGFs favor gene pairs with strong physical interactions, suggesting a mechanism similar to evolution by "tinkering" \[[@R54]\].

DISCUSSION {#s3}
==========

Distinct phylogenomic and genomic features identified through evolutionary studies of the emergence of cancer genes have provided mechanistic insights into the complexity of cancer progression in human. However, less is known about CSGFs involved genes at the genome-wide level since most existing studies focus on discovering novel fusions and testing individual molecular mechanisms \[[@R2], [@R40]\]. In this study, we show that a substantial number of CSGF involved genes arise from vertebrate whole genome duplications while the involved gene families are of bilateral origin. Consistently, conserved protein domain combinations of the cancer somatic fusion genes appear to be vertebrate specific. Our results provide molecular evidence supporting the hypothesis that the earliest cancer occurred in vertebrates \[[@R39]\]. Indeed, the earliest known unequivocal neoplastic case was found on the partial skeleton of a North American lower carboniferous (about 300 million years BP) fossil fish, *Phanerosteon mirabile* \[[@R55]\].

Distinct genomic features of CSGFs may have both theoretical and practical implications. There are clear patterns of the polarity of CSGFs: i) F5Gs appear to be less globally expressed in contrast to a recent study which showed more global expression of cancer genes; ii) the selection signatures of 3′ UTRs of 5′ UTRs are linked to an miRNA regulation network \[[@R9], [@R56]\]; iii) at the protein level, there are functional selection footprints of N-terminal degradation rules \[[@R44]\]; iv) there are intrinsic disordered signatures at the joint site of CSGFs \[[@R56]\]. Such observed structure and function relationships not only have the potential to enable us to better understand the functions of CSGFs and more accurately predict CSGFs but also implicate novel therapeutics including targeting cancer somatic fused tyrosine kinase (TK) fusions and activating multiple CSGFs simultaneously \[[@R12]\].

DNA breakpoint signatures provide new insights into the mechanisms underlying CSGFs. However, most studies focused upon germline translocation breakpoints, involving four distinct mechanisms including non-homologous end joining (NHEJ), non-allelic homologous recombination (NAHR), transposition, DNA replication mechanisms \[[@R40]\]. For somatic cases, especially for those in carcinomas, arising mechanisms have been largely unknown(26,28). These overrepresented motifs further highlight the key role of inflammation process that might cause genome instability. Given that genome instability can trigger inflammation, there may be a positive feedback loop between two hallmarks of cancer, genome instability and immune disorder \[[@R57]\]. Our study also revealed the connection of CSGFs to promoters, enhancers, H3K4me3, replication time, as well as fragile sites susceptible to rearrangements and translocations. Another important finding from our study is that a significant number of CSGFs are involved in metastasis, the core of cancer mortality.

Taken together, our findings underscore the prerequisites, causes, and consequences of CSGFs and further our knowledge of CSGFs at the evolutionary, structural and functional levels. The striking features uncovered by integration of phylogenomic, functional genomic, protein interaction data have both theoretical and clinical implications for further testing.

MATERIALS AND METHODS {#s4}
=====================

CSGF data sets and annotations {#s4_1}
------------------------------

CSGFs datasets (Table [1](#T1){ref-type="table"}), including the COSMIC \[[@R22]\], Genetech cell line fusions \[[@R5]\], TICdb \[[@R4]\], Cancer landscape fusions \[[@R7]\], Mitelman fusions \[[@R23]\], and a recent curation of the TCGA fusions \[[@R6]\], were collected. Specially, the cancer landscape fusions and COSMIC fusions are focused on driver fusions, while other data settings are mixture of a variety of different somatic fusions found in cancer.

Functional genomic data sets (Table [1](#T1){ref-type="table"}) including the reference human genomic ENSEMBL data \[[@R24]\], refined human protein coding genes (general and tissue-specific protein-protein interactions \[[@R25]\], FANTOM expression data \[[@R26], [@R27]\], GTEX data, the standard gene expression data set \[[@R29]\], Illumina\'s body map, draft human proteome, gene age curation \[[@R14]\], human gene expression atlas \[[@R33]\], as well as the TCGA data \[[@R34], [@R35]\], were also collected. Gene expression data including both mRNA level and protein level as well as protein interaction network data were tabulated in Table [1](#T1){ref-type="table"}. Evolutionary data including gene and gene family age settings have also been listed.

The TCGA SCNAs data set was downloaded from the TCGA site. For a set of high-quality and robust CNVs extracting, the thresholds of 0.2 and −0.2 for segment mean value were used to determine amplifications and deletions, respectively. For CSGFs breakpoint and TGCA SNCAs overlapping, the Granges Bioconductor class was applied in the hg19 reference genome \[[@R58]\].

Asymmetry statistics {#s4_2}
--------------------

Statistical comparisons were carried out with a non-parameter model with R functions including Wilcoxon Signed Rank or Kruskal Wallis test. The Bland-Altman plot was employed for asymmetry analysis and signal capture \[[@R59]\]. The two-sample Kolmogorov-Smirnov test was used for statistically significant test with the function 'ks.test'.

DNA breakpoint sequence motifs analysis {#s4_3}
---------------------------------------

Pan-cancer breakpoint sequences were downloaded from the TICdb (release 3.3, August 2013, <http://www.unav.es/genetica/TICdb/>) \[[@R4]\]. Meanwhile, a set of breakpoint sequences was got from literatures \[[@R5], [@R6], [@R60], [@R61]\], and sequences were mapped to the hg19 human genome with GenomicAlignment \[[@R34]\]. Motif analysis library was carried out by using the method described in the literature \[[@R62]\]. The null model of overrepresentation was based on a Fisher\'s exact test by using the R script.

Protein-protein interaction networks {#s4_4}
------------------------------------

Gene-gene connection data was downloaded from HumanNet V.1 \[[@R63]\], a probabilistic functional gene network of 18,714 validated protein-encoding genes of *Homo sapiens* (by NCBI March 2007). HumanNet was constructed by a modified Bayesian integration of 21 types of \'omics\' data from multiple organisms, with each data type weighted according to how well it links genes that are known to function together in H. Sapiens. Protein-protein interaction data and tissue specific protein interaction data networks were downloaded from the related web sites \[[@R25], [@R64]--[@R70]\]. The "igraph" package \[[@R71]\] was used to compute network properties including, degree distribution, betweenness centrality, associativity, closeness, short-path, as well as density.
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